Circumventing Drug Treatment? Intrinsic Lethal Effects of Polyethyleneimine (PEI)-Functionalized Nanoparticles on Glioblastoma Cells Cultured in Stem Cell Conditions.
brain cancer
glioblastoma
mesoporous silica nanoparticles
polyethyleneimine (PEI)
proton-sponge effect
therapy resistance
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
27 May 2021
27 May 2021
Historique:
received:
28
03
2021
revised:
02
05
2021
accepted:
20
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Glioblastoma (GB) is the most frequent malignant tumor originating from the central nervous system. Despite breakthroughs in treatment modalities for other cancer types, GB remains largely irremediable due to the high degree of intratumoral heterogeneity, infiltrative growth, and intrinsic resistance towards multiple treatments. A sub-population of GB cells, glioblastoma stem cells (GSCs), act as a reservoir of cancer-initiating cells and consequently, constitute a significant challenge for successful therapy. In this study, we discovered that PEI surface-functionalized mesoporous silica nanoparticles (PEI-MSNs), without any anti-cancer drug, very potently kill multiple GSC lines cultured in stem cell conditions. Very importantly, PEI-MSNs did not affect the survival of established GB cells, nor other types of cancer cells cultured in serum-containing medium, even at 25 times higher doses. PEI-MSNs did not induce any signs of apoptosis or autophagy. Instead, as a potential explanation for their lethality under stem cell culture conditions, we demonstrate that the internalized PEI-MSNs accumulated inside lysosomes, subsequently causing a rupture of the lysosomal membranes. We also demonstrate blood-brain-barrier (BBB) permeability of the PEI-MSNs in vitro and in vivo. Taking together the recent indications for the vulnerability of GSCs for lysosomal targeting and the lethality of the PEI-MSNs on GSCs cultured under stem cell culture conditions, the results enforce in vivo testing of the therapeutic impact of PEI-functionalized nanoparticles in faithful preclinical GB models.
Identifiants
pubmed: 34071918
pii: cancers13112631
doi: 10.3390/cancers13112631
pmc: PMC8198814
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Jane and Aatos Erkko Foundation
ID : xxxxxx
Organisme : Academy of Finland
ID : 309374
Organisme : Sigrid Jusélius Foundation
ID : xxxxxxxxx
Références
Mol Ther. 2011 Aug;19(8):1538-46
pubmed: 21629222
Cell Death Differ. 2006 Jul;13(7):1238-41
pubmed: 16456578
Int J Nanomedicine. 2014 May 06;9 Suppl 1:51-63
pubmed: 24872703
Nat Commun. 2018 Oct 31;9(1):4551
pubmed: 30382084
Adv Drug Deliv Rev. 2006 Dec 1;58(14):1523-31
pubmed: 17079050
J Gene Med. 2005 May;7(5):657-63
pubmed: 15543529
AAPS PharmSci. 2002;4(3):E12
pubmed: 12423061
Open Biol. 2018 Apr;8(4):
pubmed: 29643148
Int J Nanomedicine. 2019 Jul 19;14:5503-5526
pubmed: 31410001
PLoS One. 2014 Mar 19;9(3):e92444
pubmed: 24647355
Int J Pharm. 2019 Jun 10;564:379-409
pubmed: 31028801
Int J Nanomedicine. 2020 Nov 12;15:8875-8892
pubmed: 33209022
Molecules. 2019 Nov 26;24(23):
pubmed: 31779126
Mol Pharm. 2019 Mar 4;16(3):1009-1024
pubmed: 30698450
Adv Mater. 2018 Jun;30(24):e1703651
pubmed: 29388264
Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6242-4
pubmed: 10841526
Eur J Pharm Biopharm. 2018 Aug;129:184-190
pubmed: 29859281
Sci Rep. 2016 Jul 08;6:29247
pubmed: 27386761
Sci Rep. 2020 Jul 9;10(1):11292
pubmed: 32647151
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Trends Cancer. 2020 Mar;6(3):223-235
pubmed: 32101725
EMBO J. 2020 Jan 2;39(1):e102030
pubmed: 31774199
ACS Omega. 2018 Dec 17;3(12):17496-17510
pubmed: 31458354
Methods Mol Biol. 2008;445:77-88
pubmed: 18425443
Opt Lett. 1994 Jun 1;19(11):780-2
pubmed: 19844443
ACS Nano. 2019 Jan 22;13(1):187-202
pubmed: 30566836
Cancer Manag Res. 2018 Oct 04;10:4229-4235
pubmed: 30323678
Science. 2002 Jul 12;297(5579):259-63
pubmed: 12114629
Int J Nanomedicine. 2016 Dec 08;11:6591-6608
pubmed: 27994460
Cell Commun Signal. 2010 Dec 22;8:31
pubmed: 21176168
Cell Mol Biol Lett. 2016 Dec 13;21:29
pubmed: 28536631
Cancer Cell. 2007 Jan;11(1):69-82
pubmed: 17222791
Mater Des. 2020 Jul;192:108742
pubmed: 32394995
Mater Today Bio. 2019 Jun 12;2:100010
pubmed: 32159145
Cold Spring Harb Perspect Biol. 2014 May 22;6(10):a016857
pubmed: 24851870
Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7297-301
pubmed: 7638184
Asian Pac J Cancer Prev. ;18(1):3-9
pubmed: 28239999
J Control Release. 2002 Aug 21;82(2-3):441-54
pubmed: 12175756
J Biomed Mater Res. 2000 Sep 5;51(3):321-8
pubmed: 10880073
Brain Res Bull. 2018 Oct;143:155-170
pubmed: 30449731
Traffic. 2018 Dec;19(12):918-931
pubmed: 30125440
ACS Appl Mater Interfaces. 2020 Jul 1;12(26):29037-29055
pubmed: 32459082
Ann N Y Acad Sci. 2016 May;1371(1):30-44
pubmed: 26599521
BMC Biotechnol. 2004 Oct 15;4:23
pubmed: 15485583
Nanomaterials (Basel). 2020 May 09;10(5):
pubmed: 32397449
EMBO J. 2011 Aug 31;30(17):3481-500
pubmed: 21878991
Chem Commun (Camb). 2006 Oct 1;(37):3909-11
pubmed: 17268667
Nat Cell Biol. 2010 Mar;12(3):207-9
pubmed: 20190829
Neurochem Res. 2012 Jun;37(6):1192-200
pubmed: 22228201
Annu Rev Chem Biomol Eng. 2018 Jun 7;9:389-411
pubmed: 29618224
PLoS One. 2016 Aug 22;11(8):e0160705
pubmed: 27547955
J Vis Exp. 2019 Apr 16;(146):
pubmed: 31058900
Sci Rep. 2018 Jul 24;8(1):11122
pubmed: 30042406
ACS Omega. 2017 Jun 30;2(6):2689-2693
pubmed: 30023673
Fertil Steril. 2009 May;91(5 Suppl):2210-20
pubmed: 18501896
Mol Ther. 2005 Jun;11(6):990-5
pubmed: 15922971
PLoS One. 2015 Sep 17;10(9):e0137675
pubmed: 26378792
Bioimpacts. 2011;1(1):23-30
pubmed: 23678404
Dalton Trans. 2014 Mar 14;43(10):4115-26
pubmed: 24457531
Adv Ther (Weinh). 2019 Nov;2(11):
pubmed: 32953978
ACS Nano. 2015 Sep 22;9(9):8655-71
pubmed: 26256227
Nat Mater. 2009 Jul;8(7):543-57
pubmed: 19525947
EMBO Mol Med. 2019 Jun;11(6):
pubmed: 31068339